Refining the use and sequencing of third-line therapy in patients with metastatic colorectal cancer

Related Experiment Video

Updated: Nov 9, 2025

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.7K

Axel Grothey1

  • 1West Cancer Center and Research Institute, OneOncology, Germantown, Tennessee.

Clinical Advances in Hematology & Oncology : H&O
|April 12, 2021
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis
04:22

Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis

Published on: March 3, 2023

643
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.0K

Related Experiment Videos

Last Updated: Nov 9, 2025

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.7K
Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis
04:22

Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis

Published on: March 3, 2023

643
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K

Articles linked to this work by shared authors, journal, and citation graph.

Microsatellite Instability and Mismatch Repair Subclonality in Human Cancers: Biologic Basis, Diagnostic Pitfalls, and Therapeutic Implications with a Focus on Colorectal Cancer.

Cancers·2026

Evaluating longitudinal toxicity and adverse event in cetuximab-treated metastatic colorectal cancer: a pooled analysis from 1,302 patients in ARCAD database.

Journal of the National Cancer Institute·2026

Reproducibility of overall survival in metastatic colorectal cancer randomized trials using ARCAD-Derived external control arms.

Journal of the National Cancer Institute·2026

Genomic analysis of oesophageal carcinoma (EC) identifies recurrent mutations in histone methyltransferases as a distinctive subset.

Oncogene·2026

Prognostic Value of Liver Metastases and KRAS Mutations in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Third-Line Placebo-Controlled Trials From the ARCAD CRC Database.

Clinical colorectal cancer·2026

Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancer.

NPJ precision oncology·2026

Redefining second-line treatment strategy, sequencing, and real-world implementation in relapsed/refractory multiple myeloma: insights from the 31st Annual Congress of the European Hematology Association.

Clinical advances in hematology & oncology : H&O·2026

Neoadjuvant therapies in high-risk localized prostate cancer: past, present, and future.

Clinical advances in hematology & oncology : H&O·2026

Artificial intelligence in prostate cancer diagnosis and management: state-of-the-art approaches and emerging innovations.

Clinical advances in hematology & oncology : H&O·2026

Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directions.

Clinical advances in hematology & oncology : H&O·2026

Enzalutamide alone or combined with other pharmacologic agents for metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026

Nivolumab dose stewardship in routine Oncology practice: a real-world health-economic simulation.

Expert review of pharmacoeconomics & outcomes research·2026

Impact of the Multimodal Protocol on the Outcomes of Cancer Patients Undergoing Radical Cystectomy.

Revista do Colegio Brasileiro de Cirurgioes·2026

An Optimized Cancer Cachexia Research Model.

Current protocols·2026

Vitamin C for the prevention of complex regional pain syndrome after foot and ankle fractures or surgery: a systematic review.

European review for medical and pharmacological sciences·2026

Macrophages Are Not Welcome: Potential of CCR1/CCR2 Inhibition for Cytokine Release Prevention.

Cancer immunology research·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us